Cargando…
Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1
BACKGROUND: Natural killer (NK) cells require a functional lytic granule machinery to mediate effective antitumor responses. Evading the lytic cargo deployed at the immune synapse (IS) could be a critical step for cancer progression through yet unidentified mechanisms. METHODS: NK cell antibody-depe...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627417/ https://www.ncbi.nlm.nih.gov/pubmed/34824159 http://dx.doi.org/10.1136/jitc-2021-003224 |
_version_ | 1784606851623550976 |
---|---|
author | Darwich, Abbass Silvestri, Alessandra Benmebarek, Mohamed-Reda Mouriès, Juliette Cadilha, Bruno Melacarne, Alessia Morelli, Lapo Supino, Domenico Taleb, Alexandre Obeck, Hannah Sustmann, Claudio Losurdo, Agnese Masci, Giovanna Curigliano, Giuseppe Kobold, Sebastian Penna, Giuseppe Rescigno, Maria |
author_facet | Darwich, Abbass Silvestri, Alessandra Benmebarek, Mohamed-Reda Mouriès, Juliette Cadilha, Bruno Melacarne, Alessia Morelli, Lapo Supino, Domenico Taleb, Alexandre Obeck, Hannah Sustmann, Claudio Losurdo, Agnese Masci, Giovanna Curigliano, Giuseppe Kobold, Sebastian Penna, Giuseppe Rescigno, Maria |
author_sort | Darwich, Abbass |
collection | PubMed |
description | BACKGROUND: Natural killer (NK) cells require a functional lytic granule machinery to mediate effective antitumor responses. Evading the lytic cargo deployed at the immune synapse (IS) could be a critical step for cancer progression through yet unidentified mechanisms. METHODS: NK cell antibody-dependent cellular cytotoxicity (ADCC) is a major determinant of the clinical efficacy of some therapeutic antibodies including the anti-HER2 Trastuzumab. Thus, we screened sera of Trastuzumab-resistant HER2 +patients with breast cancer for molecules that could inhibit NK cell ADCC. We validated our findings in vitro using cytotoxicity assays and confocal imaging of the lytic granule machinery and in vivo using syngeneic and xenograft murine models. RESULTS: We found that sera from Trastuzumab-refractory patients could inhibit healthy NK cell ADCC in vitro. These sera contained high levels of the inflammatory protein chitinase 3-like 1 (CHI3L1) compared with sera from responders and healthy controls. We demonstrate that recombinant CHI3L1 inhibits both ADCC and innate NK cell cytotoxicity. Mechanistically, CHI3L1 prevents the correct polarization of the microtubule-organizing center along with the lytic granules to the IS by hindering the receptor of advanced glycation end-products and its downstream JNK signaling. In vivo, CHI3L1 administration drastically impairs the control of NK cell-sensitive tumors, while CHI3L1 blockade synergizes with ADCC to cure mice with HER2 +xenografts. CONCLUSION: Our work highlights a new paradigm of tumor immune escape mediated by CHI3L1 which acts on the cytotoxic machinery and prevents granule polarization. Targeting CHI3L1 could mitigate immune escape and potentiate antibody and cell-based immunotherapies. |
format | Online Article Text |
id | pubmed-8627417 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-86274172021-12-10 Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1 Darwich, Abbass Silvestri, Alessandra Benmebarek, Mohamed-Reda Mouriès, Juliette Cadilha, Bruno Melacarne, Alessia Morelli, Lapo Supino, Domenico Taleb, Alexandre Obeck, Hannah Sustmann, Claudio Losurdo, Agnese Masci, Giovanna Curigliano, Giuseppe Kobold, Sebastian Penna, Giuseppe Rescigno, Maria J Immunother Cancer Clinical/Translational Cancer Immunotherapy BACKGROUND: Natural killer (NK) cells require a functional lytic granule machinery to mediate effective antitumor responses. Evading the lytic cargo deployed at the immune synapse (IS) could be a critical step for cancer progression through yet unidentified mechanisms. METHODS: NK cell antibody-dependent cellular cytotoxicity (ADCC) is a major determinant of the clinical efficacy of some therapeutic antibodies including the anti-HER2 Trastuzumab. Thus, we screened sera of Trastuzumab-resistant HER2 +patients with breast cancer for molecules that could inhibit NK cell ADCC. We validated our findings in vitro using cytotoxicity assays and confocal imaging of the lytic granule machinery and in vivo using syngeneic and xenograft murine models. RESULTS: We found that sera from Trastuzumab-refractory patients could inhibit healthy NK cell ADCC in vitro. These sera contained high levels of the inflammatory protein chitinase 3-like 1 (CHI3L1) compared with sera from responders and healthy controls. We demonstrate that recombinant CHI3L1 inhibits both ADCC and innate NK cell cytotoxicity. Mechanistically, CHI3L1 prevents the correct polarization of the microtubule-organizing center along with the lytic granules to the IS by hindering the receptor of advanced glycation end-products and its downstream JNK signaling. In vivo, CHI3L1 administration drastically impairs the control of NK cell-sensitive tumors, while CHI3L1 blockade synergizes with ADCC to cure mice with HER2 +xenografts. CONCLUSION: Our work highlights a new paradigm of tumor immune escape mediated by CHI3L1 which acts on the cytotoxic machinery and prevents granule polarization. Targeting CHI3L1 could mitigate immune escape and potentiate antibody and cell-based immunotherapies. BMJ Publishing Group 2021-11-25 /pmc/articles/PMC8627417/ /pubmed/34824159 http://dx.doi.org/10.1136/jitc-2021-003224 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Clinical/Translational Cancer Immunotherapy Darwich, Abbass Silvestri, Alessandra Benmebarek, Mohamed-Reda Mouriès, Juliette Cadilha, Bruno Melacarne, Alessia Morelli, Lapo Supino, Domenico Taleb, Alexandre Obeck, Hannah Sustmann, Claudio Losurdo, Agnese Masci, Giovanna Curigliano, Giuseppe Kobold, Sebastian Penna, Giuseppe Rescigno, Maria Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1 |
title | Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1 |
title_full | Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1 |
title_fullStr | Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1 |
title_full_unstemmed | Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1 |
title_short | Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1 |
title_sort | paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1 |
topic | Clinical/Translational Cancer Immunotherapy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627417/ https://www.ncbi.nlm.nih.gov/pubmed/34824159 http://dx.doi.org/10.1136/jitc-2021-003224 |
work_keys_str_mv | AT darwichabbass paralysisofthecytotoxicgranulemachineryisanewcancerimmuneevasionmechanismmediatedbychitinase3like1 AT silvestrialessandra paralysisofthecytotoxicgranulemachineryisanewcancerimmuneevasionmechanismmediatedbychitinase3like1 AT benmebarekmohamedreda paralysisofthecytotoxicgranulemachineryisanewcancerimmuneevasionmechanismmediatedbychitinase3like1 AT mouriesjuliette paralysisofthecytotoxicgranulemachineryisanewcancerimmuneevasionmechanismmediatedbychitinase3like1 AT cadilhabruno paralysisofthecytotoxicgranulemachineryisanewcancerimmuneevasionmechanismmediatedbychitinase3like1 AT melacarnealessia paralysisofthecytotoxicgranulemachineryisanewcancerimmuneevasionmechanismmediatedbychitinase3like1 AT morellilapo paralysisofthecytotoxicgranulemachineryisanewcancerimmuneevasionmechanismmediatedbychitinase3like1 AT supinodomenico paralysisofthecytotoxicgranulemachineryisanewcancerimmuneevasionmechanismmediatedbychitinase3like1 AT talebalexandre paralysisofthecytotoxicgranulemachineryisanewcancerimmuneevasionmechanismmediatedbychitinase3like1 AT obeckhannah paralysisofthecytotoxicgranulemachineryisanewcancerimmuneevasionmechanismmediatedbychitinase3like1 AT sustmannclaudio paralysisofthecytotoxicgranulemachineryisanewcancerimmuneevasionmechanismmediatedbychitinase3like1 AT losurdoagnese paralysisofthecytotoxicgranulemachineryisanewcancerimmuneevasionmechanismmediatedbychitinase3like1 AT mascigiovanna paralysisofthecytotoxicgranulemachineryisanewcancerimmuneevasionmechanismmediatedbychitinase3like1 AT curiglianogiuseppe paralysisofthecytotoxicgranulemachineryisanewcancerimmuneevasionmechanismmediatedbychitinase3like1 AT koboldsebastian paralysisofthecytotoxicgranulemachineryisanewcancerimmuneevasionmechanismmediatedbychitinase3like1 AT pennagiuseppe paralysisofthecytotoxicgranulemachineryisanewcancerimmuneevasionmechanismmediatedbychitinase3like1 AT rescignomaria paralysisofthecytotoxicgranulemachineryisanewcancerimmuneevasionmechanismmediatedbychitinase3like1 |